Journal Article

DKFZ-2018-01906

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png 68Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients.

Koerber, S. A. (First author)DKFZ* ; Will, L. ; Kratochwil, C.DKFZ* ; Haefner, M. F.DKFZ* ; Rathke, H. ; Kremer, C. ; Merkle, J. ; Herfarth, K.DKFZ* ; Kopka, K.DKFZ* ; Choyke, P. L. ; Holland-Letz, T.DKFZ* ; Haberkorn, U.DKFZ* ; Debus, J.DKFZ* ; Giesel, F. (Last author)DKFZ*

2019
Soc. New York, NY

This record in other databases:  

Please use a persistent id in citations: doi:10.2967/jnumed.118.211086

Abstract: The present study analyzed the impact of Gallium-68 (68Ga)-labeled prostate-specific membrane antigen-HBED-CC (68Ga-PSMA-11) positron-emission tomography (PET)/computed tomography (CT) on radiotherapeutic management in a large cohort of men with primary or recurrent disease. Methods: This study investigated 121 men with carcinoma of the prostate who underwent 68Ga-PSMA-11 PET/CT as well as conventional imaging. 50 patients were treatment naive, 11 had persistent prostate-specific antigen (PSA) soon after surgery and 60 presented with recurrent PSA following definitive therapy. Changes in TNM classification of malignant tumors (TNM) stage and radiotherapeutic management after 68Ga-PSMA-11 imaging were compared to results achieved with conventional imaging. Results: In total, a change in TNM stage and radiotherapeutic management was observed for 49 patients (40.5%) and 62 patients (51.2%), respectively. In treatment naïve patients, a change in TNM stage and radiotheraeutic plan occurred in 26.0% and 44.0% of the cohort respectively. For patients with PSA persistence or recurrence, TNM and radiotherapeutic management changed in 50.7% and 56.3% respectively. Conclusion:68Ga-PSMA-11 PET/CT may shortly become an indispensable tool for detecting prostate cancer lesions in treatment-naïve patients as well as in men with recurrent disease or persistent PSA and seems to be very helpful in personalizing radiotherapeutic management to the individual patients' distribution of disease.

Note: vol. 60 no. 2 234-240

---

Contributing Institute(s):

1. E050 KKE Strahlentherapie (E050)
2. E060 KKE Nuklearmedizin (E060)
3. Radiopharmazeutische Chemie (E030)
4. DKTK Heidelberg (L101)
5. C060 Biostatistik (C060)

Research Program(s):

1. 315 - Imaging and radiooncology (POF3-315) (POF3-315)

Appears in the scientific report 2019

---

Database coverage:
; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; PubMed Central ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---